These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28463758)

  • 1. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of serum Anti-Müllerian Hormone (AMH) level in young women treated with chemotherapy for breast cancer according to basal AMH level.
    Loubersac S; Dezellus A; Lefebvre T; Reignier A; Barriere P; Masson D; Freour T;
    Eur J Obstet Gynecol Reprod Biol; 2020 Nov; 254():132-137. PubMed ID: 32971432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian Hormone.
    Drechsel KCE; Broer SL; Stoutjesdijk FS; van Dulmen-den Broeder E; Beishuizen A; Wallace WH; Körholz D; Mauz-Körholz C; Hasenclever D; Cepelova M; Uyttebroeck A; Ronceray L; Twisk JWR; Kaspers GJL; Veening MA
    Hum Reprod; 2024 Aug; 39(8):1701-1711. PubMed ID: 38794915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
    Wang S; Pei L; Hu T; Jia M; Wang S
    Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
    Wang SY; Wang S
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Lee DY; Park YH; Lee JE; Choi D
    Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
    Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
    Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
    BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
    Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
    Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
    Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
    Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
    Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
    Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
    Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
    Goldfarb SB; Turan V; Bedoschi G; Taylan E; Abdo N; Cigler T; Bang H; Patil S; Dickler MN; Oktay KH
    Breast Cancer Res Treat; 2021 Jan; 185(1):165-173. PubMed ID: 32930927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
    Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
    Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
    Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
    Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum anti-Müllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation.
    Liebenthron J; Reinsberg J; van der Ven K; Saenger N; Kruessel JS; von Wolff M
    Hum Reprod; 2019 Dec; 34(12):2513-2522. PubMed ID: 31782794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.